Oxybutynin for Hot Flashes in Women with Breast Cancer
Oxybutynin for Hot Flashes in Women with Breast Cancer
February 25, 2019 (Issue: 1566)
Interim results of a double-blind, placebo-controlled
trial suggest that off-label use of the anticholinergic
drug oxybutynin may reduce the frequency and
severity of hot flashes in women with breast cancer.
Extended-release oral oxybutynin...more
- RA Leon-Ferre et al. A randomized, double-blind, placebo-controlled trial of oxybutynin (Oxy) for hot flashes (HF): ACCRU study SC-1603. Presented at the 2018 San Antonio Breast Cancer Symposium. San Antonio, TX. December 7, 2018. Abstract available at: https://www.abstracts2view.com/ sabcs18/view.php?nu=SABCS18L_1448. Accessed February 14, 2019.
- JA Simon et al. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause 2016; 23:1214.
- Drugs for menopausal symptoms. Med Lett Drugs Ther 2016; 58:142.
- R Ramaswami et al. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015; 152:231.
- Paroxetine (Brisdelle) for hot flashes. Med Lett Drugs Ther 2013; 55:85.
- JE Desmarais and KJ Looper. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70:1688.
- JN Brown and BR Wright. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy 2009; 29:74.
- CL Loprinzi et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010; 28:641.
- KJ Pandya et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366:818.
- CR Chapple et al. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002; 60 (5 suppl 1):82.
- SL Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175:401.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. February 5, 2019. Reprinted with permission by First Databank, Inc. All rights reserved. ©2019. www.fdbhealth. com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Oxybutynin for Hot Flashes in Women with Breast Cancer
Article code: 1566d
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
